Close Menu

PCR

News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.

UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.

The Australian maker of multiplexed molecular diagnostics tests has now partnered with distributors in Germany, Austria, Sweden, and Turkey.

The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.

Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.

The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.

Oil made from gene-edited soybeans is already in use, according to the Associated Press.

Mother Jones reports there are few regulations overseeing the use of genetic genealogy by law enforcement.

USA Today reports that Department of Veterans Affairs is teaming up with Sanford Health to provide veterans with genetic testing.

In Science this week: analysis of ancient DNA recovered from Iberian populations, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.